Deoxyguanosine Market Size, Share, and Industry Analysis, By Product Type (Deoxyguanosine Monohydrate, Deoxyguanosine Triphosphate, Deoxyguanosine Monophosphate, and Others), By Physical Form (Solid and Liquid), By Application (Therapeutics, Diagnostics, and Research & Development), By End-user (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, and Others), and Regional Forecast, 2025-2032

The global deoxyguanosine market is witnessing substantial growth due to an increasing number of research activities in the genomics and molecular biology. Deoxyguanosine is a nucleoside consisting of the nitrogenous base guanine attached to the deoxyribose sugar. The nucleotide deoxyguanosine triphosphate is a precursor and a critical building block for DNA synthesis. Thus, it is a critical component for DNA synthesis. Furthermore, the advancements in genetic research, drug development, and diagnostic technologies have increased the product demand, propelling market growth. Furthermore, the increasing fundraising activities for the research and development for DNA synthesis as the nucleotide deoxyguanosine triphosphate is a precursor for DNA synthesis, and thus this scenario is expected to propel the adoption of deoxyguanosine and boost the growth of the market.

• In April 2022, Ansa Biotechnologies, Inc. announced that they had raised USD 68.0 million in the series A funding with an aim to support the company's research and development activities for DNA synthesis and to launch customizable services. Such scenarios promote the growth of the market.

Deoxyguanosine Market Driver

Increasing Demand for Synthetic DNA to Propel Market Growth

The rising prevalence of chronic diseases such as cancer and autoimmune disorders leads to an increased demand for synthetic DNA for the development of new drugs, gene therapies, and vaccines. Such scenarios boosted the utilization of deoxyguanosine as the precursor for the production of synthetic DNA. The increasing initiatives by companies to launch advanced technologies for the DNA synthesis drive the growth of the market.

• For instance, in May 2024, Molecular Assemblies, Inc. launched a Partnering Program to license the company's Fully Enzymatic Synthesis (FES) technology for onsite synthesis. This technology accelerates the production of long, pure, and accurate DNA to propel therapeutics and diagnostics. Such scenarios drive the demand for deoxyguanosine, pushing the growth of the market.

Download Free sample to learn more about this report.

The World Health Organization (WHO) has projected that the global cancer cases would increase from 20 million in 2022 to 35 million in 2050.

Deoxyguanosine Market Restraint

High Cost Associated with Deoxyguanosine May Limit the Market Growth

The high cost associated with the product limits its accessibility for smaller research labs and constrains the academic research budget.

• As per a commercial website, five grams of 2′-Deoxyguanosine monohydrate by Merck KGaA cost around USD 1,633.6. Such high costs may hamper the growth of the market.

Deoxyguanosine Market Opportunity

Rising Demand for Synthetic Biology Products Augments Fundraising Efforts

Due to the increasing demand for synthetic biology products, various organizations are prioritizing their fundraising efforts to enhance their capabilities in the development of advanced DNA-based products.

• In April 2023, NunaBio raised USD 2.3 million in funding to expand the infrastructure and advance research to develop a novel method of DNA synthesis. Such activities increase the usage of deoxyguanosine as a starting reagent for DNA synthesis and are expected to enhance the growth of the market during the forecast period.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Countries/ Regions, 2023
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Product Launches)
• Regulatory Overview, By Key Countries/Regions
• Impact of COVID-19 on the Market

Segmentation

Analysis by Product Type

By product type, the market is segmented into deoxyguanosine monohydrate, deoxyguanosine triphosphate, deoxyguanosine monophosphate, and others.

Deoxyguanosine triphosphate is one of the nucleoside triphosphates required for the synthesis of DNA. The rising demand for synthetic DNA and increasing strategic initiatives among key healthcare players to adopt synthetic DNA technology for the personalized medicine, gene therapy, vaccine development, and others have led to the growth of the segment in the market.

• In January 2024, Elegen collaborated with GSK to leverage the company's cell-free DNA manufacturing technology in the development of GSK's vaccines and medicines. Such advancements propel the demand for deoxyguanosine market as an important reagent for DNA production. 

Analysis by Physical Form

By physical form, the market is subdivided into solid and liquid.

The solid segment accounts for a substantial share of the market. A large variety of deoxyguanosine is present in the solid powder or crystalline powder form. The significant market share is due to their stability, ease of handling, long shelf life, and versatility for various applications.

• For instance, Merck KGaA offers 2′-Deoxyguanosine monohydrate in the solid powder form.

Analysis by Application

On the basis of application, the market is segmented into therapeutics, diagnostics, and research & development.

The research & development segment held a significant share of the market. The growth of the segment is attributed to the increasing research and development activities for drug discovery & development, genetic engineering, and diagnostics. The robust initiatives by key companies to advance their research and development activities and increase their funding activities are expected to propel the segment growth.

• For instance, in February 2023, the European Innovation Council (EIC) awarded USD 2.67 million to Exactmer for their ground-breaking research in the synthesis and manufacture of oligonucleotide (oligo) therapeutics. Such scenarios boost the growth of the segment.

Analysis by End-user

Based on end-user, the market is subdivided into pharmaceutical and biotechnology companies, research and academic institutes, and others.

The pharmaceutical and biotechnology companies held a significant share of the market. The growth of the segment is due to the advanced infrastructure and the availability of skilled professionals, which facilitate the adoption of deoxyguanosine-based products in research and development for launching drugs and vaccines in the market.

• For instance, in May 2024, Integrated DNA Technologies opened a new manufacturing facility for the expansion of its synthetic biology operations to enhance its gene synthesis portfolio with differentiated offerings.

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America accounted for a substantial share of the global deoxyguanosine market in 2023. The growth of the market in the region is attributed to the advanced research facilities and infrastructure in the region. Furthermore, active fundraising initiatives result in the expansion of the synthetic biology workflow, contributing to the regional dominance.

• For instance, in 2024, according to data published by the American Cancer Society, Inc., an estimated 2,001,140 new cancer cases are set to be registered in the U.S. Such an increasing number of cases requires early and precise diagnostics method, leading to the adoption of deoxyguanosine for DNA synthesis in the region.

Europe is the second-largest market based on the demand for deoxyguanosine. Within Europe, there are increasing research activities and the presence of key players in the market.

• The U.K. research councils established the Synthetic Biology for Growth program and invested around USD 126.9 million in synthetic biology research.

The rising patient population, growing healthcare infrastructure, and advancements in synthetic biology solutions led to the growth of the Asia Pacific region in the market.

Key Players Covered

The global deoxyguanosine market reflects a fragmented structure. The global market has the presence of a large number of established and emerging companies, with some of the companies being prominent players in the life sciences industry.

The report includes the profiles of the following key players:

• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• MP BIOMEDICALS. (U.S.)
• TriLink BioTechnologies (U.S.)
• Biosynth (Switzerland)
• Spectrum Chemical (U.S.)
• Cambridge Bioscience Limited (U.K.)
• SimSon Pharma Limited (India)
• Chemicea Limited (India)
• Bright Pharma Luna Chemicals (China)

Key Industry Developments

• In July 2024, Cambridge Bioscience Limited, a life science research and diagnostic products company, collaborated with AssayQuant Technologies with the aim of accelerating drug development and supporting faster lead identification, characterization, profiling, and optimization. This collaboration would lead to an increase in the adoption of deoxyguanosine for drug development.
• In May 2024, TriLink BioTechnologies collaborated with Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. The move would further help accelerate research and therapeutic development with RNA synthesis technology that require deoxyguanosine as a precursor.